Evidence map›Paper›PMID 29254108›Full record

ReviewJournal of Parkinson's disease2018

Using Medical Claims Analyses to Understand Interventions for Parkinson Patients.

Bastiaan R Bloem, Jan H L Ypinga, Allison Willis, Colleen G Canning, Roger A Barker, Marten Munneke, Nienke M De Vries

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of Parkinson's disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 2 pooled it
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Claims-Based Frailty and Outcomes: Applying an Aging Measure to Older Adults with Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2021
    Observational
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Observational
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 4 countries.

Bastiaan R BloemDepartment of Neurology, Radboud University Medical Center, Donders Institute for Brain, Cognition and Behavior, Nijmegen, The Netherlands.
Jan H L YpingaDepartment Care Purchasing, CZ Groep, Goes, The Netherlands.
Allison WillisDepartments of Neurology and of Biostatistics, Epidemiology and Informatics, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.
Colleen G CanningDiscipline of Physiotherapy, Faculty of Health Sciences, University of Sydney, Sydney, Australia.
Roger A BarkerDepartment of Clinical Neurosciences, John van Geest Centre for Brain Repair, University of Cambridge, UK.
Marten MunnekeDepartment of Neurology, Radboud University Medical Center, Donders Institute for Brain, Cognition and Behavior, Nijmegen, The Netherlands.
Nienke M De VriesDepartment of Neurology, Radboud University Medical Center, Donders Institute for Brain, Cognition and Behavior, Nijmegen, The Netherlands.
Radboud University Nijmegen · NLThe University of Sydney · AUUniversity of Cambridge · GBUniversity of Pennsylvania · US

Funding

Impact of Anticholinergic and Dopamine Receptor Blocking Drug Exposure on Parkinson Disease Trajectory and OutcomesR01NS099129 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI WILLIS, ALLISON · 2017 to 2021
$2.9M
NINDS NIH HHS R01 NS099129
6 · The paper itself

Abstract

The scientific evidence to support the value of a range of non-pharmacological interventions for people with Parkinson's disease (PD) is increasing. However, showing unequivocally that specific interventions are better than usual care is not straightforward because of generic drawbacks of clinical trials. Here, we address these challenges, specifically related to the context of evaluating complex non-pharmacological interventions for people with PD. Moreover, we discuss the potential merits of undertaking "real world" analyses using medical claims data. We illustrate this approach by discussing an interesting recent publication in The Lancet Neurology, which used such an approach to demonstrate the value of specialized physiotherapy for PD patients, over and above usual care physiotherapy.

Indexed as

Physical Therapy ModalitiesCost-Benefit AnalysisCost SavingsFollow-Up StudiesForecastingHumansInsurance Claim ReviewNetherlandsParkinson DiseaseQuality of LifeRandomized Controlled Trials as TopicTreatment OutcomeCost-effectivenessmedical claimsParkinsonNetParkinson’s diseasephysical therapy

Identifiers

PMID29254108
PMCPMC5836412
OpenAlexW2774393303

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.